Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.

The user is experiencing insomnia after starting finasteride and is seeking solutions without quitting the medication. Suggestions include trying ZMA, maintaining consistent sleep habits, and considering other sleep aids like Nytol or melatonin.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The user applies 2ml of a lotion containing 5% minoxidil, 0.3% finasteride, hydrocortisone butyrate, and cetirizine before bed, but it leaves a residue on the scalp. Another user suggests reducing the amount to 1ml, as 2ml results in a high finasteride dosage.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

The user has been using topical melatonin spray with finasteride and dutasteride to reduce hair shedding but dislikes the lavender scent of their current spray. They are seeking recommendations for a scentless or better-smelling melatonin spray.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.

Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The conversation is about hair loss treatments, specifically discussing Clascoterone (5%) availability in UK or EU pharmacies. Users also mention pyrilutamide and its availability from Kintor as a cosmetic.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A user is considering using melatonin for hair recovery on the side and neck area but is unsure about the best options in Europe and whether a dietary supplement form can be applied to the scalp. They found a product but are hesitant and seeking opinions on its use for alopecia.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.